Top Markets
#1 CoW Protocol CoW Protocol +59.73%
#2 EXOD EXOD +56.80%
#3 Glidr Glidr +39.17%
#4 Cysic Cysic +31.67%
#5 Walrus Walrus +25.40%
#6 Humanity Humanity +22.30%
#7 Enso Enso +17.07%
#8 Velvet Velvet +17.00%
#9 Tutorial Tutorial +16.94%
#10 Huma Finance Huma Finance +14.02%
Coin of the day
CoW Protocol CoW Protocol
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited

ASLN
Classifica tra le azioni #37031
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the... ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions. The company is involved in a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., aimed at pioneering immuno-oncology therapeutics that target the AhR pathway. Furthermore, ASLAN maintains partnerships with various entities, including Almirall, Array BioPharma, and CSL Limited. Established in 2010, the company's headquarters are located in Singapore.
Prezzo delle azioni
$0.6
Ultima sincronizzazione: 2024-08-14
Capitalizzazione di mercato
$2.09M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
SG
Scambia ASLAN Pharmaceuticals Limited (ASLN)

Categoria

Healthcare
Rapporto P/S per ASLAN Pharmaceuticals Limited (ASLN)
Rapporto P/S al August 2026 TTM: 64.76
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di ASLAN Pharmaceuticals Limited, il rapporto P/S attuale (TTM) è 64.76. Alla fine del 2022, era pari a 0.00.
Storico del rapporto P/S per ASLAN Pharmaceuticals Limited da 2014 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
2026 (TTM) 64.76 28,056.61%
2023 0.23 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 -100.00%
2019 7.03 0.00%
2018 0.00 0.00%
2017 0.00 -100.00%
2016 4.07 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -84.30%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -84.36%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 -92.68%
BE